Genetically Determined Variability in Acetylation and Oxidation Therapeutic Implications
- 1 April 1985
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 29 (4), 342-375
- https://doi.org/10.2165/00003495-198529040-00003
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Antibodies to Nuclear Antigens in Patients Treated with Procainamide or AcetylprocainamideNew England Journal of Medicine, 1979
- Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazineThe Journal of Pediatrics, 1979
- Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotypeJournal of Pharmacokinetics and Biopharmaceutics, 1979
- Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamineXenobiotica, 1979
- Gilbert??s Syndrome and Drug MetabolismClinical Pharmacokinetics, 1979
- Effect of Acetylator Phenotype on the Rate at Which Procainamide Induces Antinuclear Antibodies and the Lupus SyndromeNew England Journal of Medicine, 1978
- Hypotensive response to debrisoquine and hydroxylation phenotypeLife Sciences, 1978
- Drugs and GenesDrugs, 1977
- Disease and Acetylation PolymorphismClinical Pharmacokinetics, 1977
- Drug-Induced Antinuclear Antibodies and Lupus SyndromesDrugs, 1976